Last Updated : June 9, 2023
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
| Brand Name | Generic Name | Therapeutic Area | Recommendation Type Sort descending | Project Status | Date Submission Received | Date Recommendation Issued |
|---|---|---|---|---|---|---|
| TBC | filgotinib | Arthritis, Rheumatoid | Withdrawn | |||
| Keytruda | Pembrolizumab | |||||
| TBC | etonogestrel | Prevention of pregnancy | Withdrawn | |||
| Tecentriq | Atezolizumab | Withdrawn | ||||
| Imbruvica | Ibrutinib | |||||
| Kineret | anakinra | Still's disease | Withdrawn | |||
| Aduhelm | aducanumab | Alzheimer’s disease | Withdrawn | |||
| Keytruda and Lenvima | pembrolizumab and lenvatinib | Advanced endometrial cancer | Withdrawn | |||
| Tysabri | natalizumab | Multiple Sclerosis, relapsing-remitting | Withdrawn | |||
| Breo Ellipta | fluticasone furoate/vilanterol | Asthma | Withdrawn |
Last Updated : June 9, 2023